CN112533602A - Axl激酶抑制剂及其用途 - Google Patents

Axl激酶抑制剂及其用途 Download PDF

Info

Publication number
CN112533602A
CN112533602A CN201980033174.9A CN201980033174A CN112533602A CN 112533602 A CN112533602 A CN 112533602A CN 201980033174 A CN201980033174 A CN 201980033174A CN 112533602 A CN112533602 A CN 112533602A
Authority
CN
China
Prior art keywords
subject
compound
cancer
inhibitor
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980033174.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·赛迪奎-贾因
S·L·沃纳
P·弗林
D·J·比尔斯
J·M·福尔克斯
N·富松
K·藤村
H·梅原
A·野野山
A·木口屋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Oncology Inc
Original Assignee
Sumitomo Pharma Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Oncology Inc filed Critical Sumitomo Pharma Oncology Inc
Publication of CN112533602A publication Critical patent/CN112533602A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
CN201980033174.9A 2018-04-05 2019-04-05 Axl激酶抑制剂及其用途 Pending CN112533602A (zh)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201862653394P 2018-04-05 2018-04-05
US62/653,394 2018-04-05
US201862663146P 2018-04-26 2018-04-26
US62/663,146 2018-04-26
US201862678980P 2018-05-31 2018-05-31
US62/678,980 2018-05-31
US201862688161P 2018-06-21 2018-06-21
US62/688,161 2018-06-21
US201862695609P 2018-07-09 2018-07-09
US62/695,609 2018-07-09
US201862698638P 2018-07-16 2018-07-16
US62/698,638 2018-07-16
US201862760882P 2018-11-13 2018-11-13
US62/760,882 2018-11-13
US201862767475P 2018-11-14 2018-11-14
US62/767,475 2018-11-14
US201862778856P 2018-12-12 2018-12-12
US62/778,856 2018-12-12
US201962813705P 2019-03-04 2019-03-04
US62/813,705 2019-03-04
PCT/US2019/026094 WO2019195753A1 (en) 2018-04-05 2019-04-05 Axl kinase inhibitors and use of the same

Publications (1)

Publication Number Publication Date
CN112533602A true CN112533602A (zh) 2021-03-19

Family

ID=68101236

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980033174.9A Pending CN112533602A (zh) 2018-04-05 2019-04-05 Axl激酶抑制剂及其用途

Country Status (13)

Country Link
US (3) US11013741B1 (https=)
EP (1) EP3773591A4 (https=)
JP (1) JP2021524835A (https=)
KR (1) KR20210003780A (https=)
CN (1) CN112533602A (https=)
AU (1) AU2019247498A1 (https=)
BR (1) BR112020020246A8 (https=)
CA (1) CA3096984A1 (https=)
IL (1) IL277600A (https=)
MX (1) MX2020010437A (https=)
PH (1) PH12020551853A1 (https=)
SG (1) SG11202009443RA (https=)
WO (1) WO2019195753A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023134582A1 (zh) * 2022-01-14 2023-07-20 上海立森印迹医药技术有限公司 一种嘧啶-2,4-二胺衍生物及其制备方法和用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
CN112533602A (zh) 2018-04-05 2021-03-19 大日本住友制药肿瘤公司 Axl激酶抑制剂及其用途
MX2021000977A (es) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
WO2021067772A1 (en) * 2019-10-04 2021-04-08 Sumitomo Dainippon Pharma Oncology, Inc. Axl inhibitor formulations
US12577211B2 (en) 2020-06-29 2026-03-17 Bacainn Biotherapeutics, Ltd. Probenecid compounds for the treatment of inflammasome-mediated lung disease
KR20230050349A (ko) * 2020-07-19 2023-04-14 아라바이브 인크. Axl 유인 수용체를 이용한 암의 진단 방법
WO2024097229A1 (en) * 2022-11-04 2024-05-10 Bacainn Biotherapeutics, Inc. Probenecid compounds for the treatment of inflammasome-mediated dermatological conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1182421A (zh) * 1995-04-27 1998-05-20 曾尼卡有限公司 喹唑啉衍生物
US20110212077A1 (en) * 2005-11-01 2011-09-01 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US20120283261A1 (en) * 2011-04-01 2012-11-08 Bearss David J Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
DE69624081T2 (de) 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
WO1998007697A1 (en) 1996-08-23 1998-02-26 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
NZ330571A (en) 1996-10-01 1999-10-28 Kyowa Hakko Kogyo Kk Nitrogenous heterocyclic compounds that may contain sulphur or oxygen
WO1998030566A1 (en) 1997-01-06 1998-07-16 Pfizer Inc. Cyclic sulfone derivatives
EP0977733B1 (en) 1997-02-03 2003-09-03 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
EA002546B1 (ru) 1997-02-11 2002-06-27 Пфайзер Инк. Производные арилсульфонилгидроксамовой кислоты
AU730248B2 (en) 1997-08-08 2001-03-01 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
JP4462654B2 (ja) 1998-03-26 2010-05-12 ソニー株式会社 映像素材選択装置及び映像素材選択方法
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
DK1004578T3 (da) 1998-11-05 2004-06-28 Pfizer Prod Inc 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
AU776788C (en) 1998-12-16 2005-10-27 Warner-Lambert Company Treatment of arthritis with MEK inhibitors
US6511993B1 (en) 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
IN191496B (https=) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
EP1257546A1 (en) 2000-02-17 2002-11-20 Amgen Inc. Kinase inhibitors
BR0111280A (pt) 2000-06-05 2003-06-10 Dong A Pharm Co Ltd Novos derivados de oxazolidinona e um processo para a preparação dos mesmos
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
AU8544901A (en) 2000-08-18 2002-03-04 Cor Therapeutics Inc Quinazoline derivatives as kinase inhibitors
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
RU2343148C2 (ru) 2002-02-01 2009-01-10 Райджел Фармасьютикалз, Инк Соединения 2,4-пиримидиндиаминов и их применение
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003224672B2 (en) 2002-03-08 2010-02-04 Eisai R&D Management Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
JP4608852B2 (ja) 2002-10-15 2011-01-12 チッソ株式会社 液晶性ビニルケトン誘導体およびその重合体
JP2006151810A (ja) 2002-12-26 2006-06-15 Daiichi Asubio Pharma Co Ltd ジヒドロチエノキノリン誘導体及びそれを含む細胞接着阻害剤
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
NZ585188A (en) 2003-08-15 2011-09-30 Novartis Ag 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
MXPA06003054A (es) 2003-09-18 2006-05-31 Novartis Ag 2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos.
AU2004282179B2 (en) 2003-10-14 2011-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors
WO2005082892A2 (en) 2004-02-17 2005-09-09 Dr. Reddy's Laboratories Ltd. Triazole compounds as antibacterial agents and pharmaceutical compositions containing them
AU2005233584B2 (en) 2004-04-09 2010-12-09 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
US20090029982A1 (en) 2005-04-28 2009-01-29 Supergen, Inc. Protein kinase inhibitors
EP1883302A4 (en) 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc JAK KINASE HEMMER AND ITS USE
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
WO2007020888A1 (ja) 2005-08-12 2007-02-22 Takeda Pharmaceutical Company Limited 脳・神経細胞保護剤および睡眠障害治療薬
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
KR20080098490A (ko) 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
RU2008152195A (ru) 2006-06-15 2010-07-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) 2-анилино-4-(гетероциклил)аминопиримидины, как ингибиторы протеинкиназы с-альфа
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
WO2008055233A1 (en) 2006-10-31 2008-05-08 Supergen, Inc. Protein kinase inhibitors
CA2668286C (en) 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
EP2311807B1 (en) 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
AR065015A1 (es) 2007-01-26 2009-05-13 Smithkline Beecham Corp Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
US8846704B2 (en) 2007-01-31 2014-09-30 YM Biosciences Austraila Pty Ltd Thiopyrimidine-based compounds and uses thereof
CN101657431A (zh) 2007-03-01 2010-02-24 休普基因公司 嘧啶-2，4-二胺衍生物及其作为jak2激酶抑制剂的用途
MX2009009117A (es) 2007-03-01 2009-09-03 Supergen Inc Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
WO2008118823A2 (en) 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
IL295053A (en) 2007-03-28 2022-09-01 Pharmacyclics Llc Broton tyrosine kinase inhibitors
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
EP2139869A2 (en) 2007-04-13 2010-01-06 SuperGen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
EP2148874B1 (en) 2007-05-04 2012-02-08 Irm Llc Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
WO2009010794A1 (en) 2007-07-19 2009-01-22 Astrazeneca Ab 2,4-diamino-pyrimidine derivatives
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
EP2234986A2 (en) 2007-12-20 2010-10-06 Cellzome Limited Sulfamides as zap-70 inhibitors
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
ES2660418T3 (es) 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
US20100029675A1 (en) 2008-07-25 2010-02-04 Hwang Soo-In Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use
MX2011001426A (es) 2008-08-05 2011-03-21 Targegen Inc Metodos para tratar la talasemia.
PL2565193T3 (pl) 2009-01-23 2014-07-31 Rigel Pharmaceuticals Inc Kompozycje i sposoby hamowania szlaku JAK
US20100204221A1 (en) 2009-02-09 2010-08-12 Hariprasad Vankayalapati Pyrrolopyrimidinyl axl kinase inhibitors
US20120040955A1 (en) 2009-04-14 2012-02-16 Richard John Harrison Fluoro substituted pyrimidine compounds as jak3 inhibitors
EP2475375A4 (en) 2009-09-09 2013-02-20 Avila Therapeutics Inc PI3 KINASE INHIBITORS AND USES THEREOF
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
WO2011046970A1 (en) 2009-10-12 2011-04-21 Myrexis, Inc. Amino - pyrimidine compounds as inhibitors of tbkl and/or ikk epsilon
AR080057A1 (es) 2010-01-29 2012-03-07 Otsuka Pharma Co Ltd Piridinas disustituidas como anticancerigenos
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
BR112012027995A2 (pt) * 2010-06-18 2017-01-10 Genentech Inc anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
WO2012135641A2 (en) 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center And Research Institute Aurora kinase inhibitors and methods of making and using thereof
EP2694486B1 (en) 2011-04-01 2018-01-10 University of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
WO2013059738A2 (en) 2011-10-19 2013-04-25 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
CN103087077B (zh) 2011-11-03 2016-05-18 上海希迈医药科技有限公司 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
WO2013173518A1 (en) 2012-05-16 2013-11-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
US8703981B2 (en) 2012-08-03 2014-04-22 Xerox Corporation Lignosulfonate compounds for solid ink applications
BR112015002709B1 (pt) 2012-08-06 2022-09-20 Acea Biosciences Inc Compostos, composição farmacêutica, uso dos mesmos e uso de uma combinação de composto ou composição farmacêutica e um segundo agente profilático ou agente terapêutico
KR101446742B1 (ko) 2012-08-10 2014-10-01 한국화학연구원 Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN104684555A (zh) * 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
CN104812756A (zh) 2012-09-26 2015-07-29 曼凯德公司 多激酶通路抑制剂
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
AU2014214846A1 (en) 2013-02-08 2015-07-23 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US10322125B2 (en) 2013-02-22 2019-06-18 Emory University TGF-beta enhancing compositions for cartilage repair and methods related thereto
WO2014130693A1 (en) 2013-02-25 2014-08-28 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
JP2016512549A (ja) 2013-03-14 2016-04-28 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
JP6473133B2 (ja) 2013-03-15 2019-02-20 アラクセス ファーマ エルエルシー Ｋｒａｓｇ１２ｃの共有結合性阻害剤
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
HK1215374A1 (zh) 2013-04-08 2016-08-26 Pharmacyclics Llc 依鲁替尼联合疗法
JP6458018B2 (ja) 2013-07-02 2019-01-23 ファーマサイクリックス エルエルシー キナーゼ阻害剤としてのプリノン化合物
CA2925124A1 (en) 2013-09-30 2015-04-02 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
AU2014331794C1 (en) 2013-10-10 2019-09-12 Araxes Pharma Llc Inhibitors of KRAS G12C
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
EP3237408B1 (en) * 2014-12-23 2018-10-31 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives
ES2739749T3 (es) 2015-05-18 2020-02-03 Tolero Pharmaceuticals Inc Profármacos de alvocidib que tienen biodisponibilidad aumentada
EP3380602A4 (en) 2015-11-23 2019-09-25 Trustees of Boston University METHOD AND COMPOSITIONS RELATED TO CHIMERIC ANTIGEN RECEPTORS
CN112533602A (zh) 2018-04-05 2021-03-19 大日本住友制药肿瘤公司 Axl激酶抑制剂及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1182421A (zh) * 1995-04-27 1998-05-20 曾尼卡有限公司 喹唑啉衍生物
US20110212077A1 (en) * 2005-11-01 2011-09-01 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US20120283261A1 (en) * 2011-04-01 2012-11-08 Bearss David J Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JANE ANTONY ET AL.,: "AXL-Driven EMT State as a Targetable Conduit in Cancer" *
KATIA REA ET AL.,: "Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023134582A1 (zh) * 2022-01-14 2023-07-20 上海立森印迹医药技术有限公司 一种嘧啶-2,4-二胺衍生物及其制备方法和用途

Also Published As

Publication number Publication date
SG11202009443RA (en) 2020-10-29
MX2020010437A (es) 2021-01-29
EP3773591A1 (en) 2021-02-17
IL277600A (en) 2020-11-30
WO2019195753A1 (en) 2019-10-10
BR112020020246A2 (pt) 2021-01-12
BR112020020246A8 (pt) 2022-10-18
US20210205304A1 (en) 2021-07-08
US20230165857A1 (en) 2023-06-01
EP3773591A4 (en) 2021-12-22
KR20210003780A (ko) 2021-01-12
AU2019247498A1 (en) 2020-11-26
PH12020551853A1 (en) 2021-07-19
US11013741B1 (en) 2021-05-25
US11400091B2 (en) 2022-08-02
JP2021524835A (ja) 2021-09-16
CA3096984A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
US11400091B2 (en) AXL kinase inhibitors and use of the same
CN109819649B (zh) 氨基嘌呤化合物的固体形式及其使用方法
ES2823756T3 (es) Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
JP2023022190A (ja) 癌治療
US11746103B2 (en) ALK-5 inhibitors and uses thereof
US11529350B2 (en) Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
US20240033266A1 (en) Combination therapy involving diaryl macrocyclic compounds
CN105473142A (zh) 用二氢吡嗪并-吡嗪治疗癌症
US20240197729A1 (en) ALK-5 Inhibitors and Uses Thereof
US20240360135A1 (en) Imidazo[1,2-b]pyridazinyl compounds and uses thereof
JP7541512B2 (ja) プロドラッグおよびその医学的使用
US20240091226A1 (en) Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor
US20230090742A1 (en) Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors
WO2022204720A1 (en) (furopyrimidin-4-yl)piperazine compounds and uses thereof
WO2019183385A1 (en) Mapk/erk inhibition for ovarian and other cancers
BR112019027967A2 (pt) forma b cristalina isolada, composição farmacêutica, método para o tratamento de um distúrbio, método de um composto ou composição, e, processo para produzir forma b cristalina.
NZ629860B (en) Methods for treating cancer using tor kinase inhibitor combination therapy
HK1151238A (en) Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Massachusetts

Applicant after: Sumitomo pharmaceutical oncology Co.,Ltd.

Address before: Massachusetts

Applicant before: Sumitomo pharmaceutical oncology Co.,Ltd.

CB02 Change of applicant information
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210319

WD01 Invention patent application deemed withdrawn after publication